HS-IT101 Injection in the Treatment of Advanced Melanoma

Summary

Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced melanoma.

Timeline

Start

2025-07-10

Primary completion

2026-05-30

Completion

2027-05-30

Drugs

Indications